Archived research. Equity coverage is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
NVO
Disclosure: As of 2026-07-03, the Runchey Research Model Trading Fund holds a long position in NVO. View our full Editorial Integrity & Disclosure Policy.
20-F Annual Report: All Signals Confirmed
FY2025 20-F review confirms FRAGILE revenue (gross margin -369 bps, Ozempic deceleration to +5.6%), ELEVATED regulatory exposure, and CONTESTED competitive position. Key new data: USD 4.2B 340B windfall in Q1 2026, DKK 130.6B manufacturing buildout, and two new securities class actions. No signal changes.
Read the full analysis"Is Novo Nordisk's GLP-1 dominance ending, or is the 40-66% stock decline an overreaction to temporary headwinds?"
**UPDATE (Feb 3, 2026):** Management guided for -5% to -13% revenue decline in 2026, a dramatic reversal from growth. Stock down 13% on the news. REVENUE_DURABILITY downgraded from CONDITIONAL to FRAGILE. Original: Novo Nordisk lost 9.3pp of global GLP-1 market share to Eli Lilly. MFN pricing agreement is now the primary headwind.
Executive Summary
Cross-lens roll-up assessment
**MATERIAL UPDATE (Feb 3, 2026):** Novo Nordisk has moved from a value rotation candidate to a restructuring story. Management's guidance for -5% to -13% revenue decline in 2026 (reversing from +10% growth in 2025) triggered REVENUE_DURABILITY downgrade to FRAGILE. The MFN agreement with US Administration creates structural pricing ceiling; US Operations already contracted -7% in Q4 2025. The bull case now requires: revenue decline at shallow end (-5%), Wegovy pill creating growth, CagriSema delivering >20% weight loss, and Lilly stumbles.
Signal downgrade to FRAGILE reflects explicit management acknowledgment of revenue contraction. This is now a restructuring story, not a growth story. Key triggers: Q1 2026 revenue trajectory, Wegovy pill adoption rate, CagriSema REDEFINE 4, MFN implementation details.
Key Takeaways
- •**SIGNAL CHANGE:** REVENUE_DURABILITY downgraded CONDITIONAL → FRAGILE: management guides -5% to -13% revenue decline; US already contracting -7% Q4
- •MFN agreement with US Administration creates structural pricing ceiling for Medicare Part D, Medicaid, and self-pay (Wegovy $199/month offers)
- •REGULATORY_EXPOSURE (ELEVATED) and COMPETITIVE_POSITION (CONTESTED) unchanged; regulatory materializing as expected, 9.3pp market share loss confirmed
- •CagriSema REDEFINE 4 and Wegovy pill adoption (~50K weekly Rx at launch) are now critical swing factors for potential recovery
Key Tensions
- •Guidance range is wide (-5% to -13%); shallow end could stabilize narrative, deep end confirms structural decline
- •Wegovy pill at ~50K weekly Rx: net volume growth or injectable cannibalization?
- •Patent expiry in international markets adds new geographic risk not previously quantified
- •Stock down 13% on guidance but already down 40-66% from peak. Is bear case priced in?
Gravy Gauge
Is revenue durable or fragile?
Key Metrics
Key FindingsClick to expand details
Signal AssessmentsClick for full context
| Signal | Scale | Assessment | Evidence |
|---|---|---|---|
Revenue Durability | FRAGILE | 1Single Source | |
Regulatory Exposure | ELEVATED | 2Corroborated |
Model Debates
Cross-Lens Insights
Where Lenses Agree
- 20-F CONFIRMATION: All signals confirmed with full-year data (Feb 19, 2026)
- SIGNAL CHANGE: Revenue now FRAGILE (Feb 3, 2026)
- Regulatory exposure is ELEVATED: confirmed, not upgraded
- CagriSema and Wegovy pill are now critical recovery vectors
The following publicly available documents were collected and extracted into a structured fact dossier that powered this analysis.
SEC Filing
- Annual Report (20-F) — FY2025 (Feb 4, 2026)
- Annual Report (20-F) — FY2024
- Current Report (6-K) — Q4 2025 (Feb 2, 2026)
- Current Report (6-K) — Q4 2025 (Jan 31, 2026)
- Current Report (6-K) — Q3 2025 (Dec 22, 2025)
- Current Report (6-K) — Q3 2025 (Nov 25, 2025)
Earnings Transcript
- Q4 2025 / FY2025 Earnings Call (Feb 4, 2026)
- Q3 2025 Earnings Call Transcript
Research Document
- FDA Compounding Regulatory Update
- Bear Case Summary